Xintela

Hans-Joachim Simons (born 1962) is the founder and Managing Partner of Bluerock Healthcare Advisors, a dedicated healthcare consultancy firm, and has significant experience in the medtech-, biotech- and pharmaceutical industry. He has served in senior positions at Gambro AB, Karl Storz Endoscopy, as General Manager for Ivy Sports Medicine that was subsequently acquired by Stryker, and as a member of the Executive Board of Medical Park AG, a leading clinic group in Germany and for Codon AG, a cell therapy company in Berlin, Germany. He currently serves as a member of the Board of Arthromeda Inc. in Boston, USA.

Hans-Joachim holds an MD and PhD from the Heinrich-Heine-University in Düsseldorf, Germany and an executive MBA from the Business School of Stellenbosch University, South Africa. Hans-Joachim is qualified surgeon.

“I am delighted that Hans-Joachim has agreed to join our Board. With his long international experience in the industry, particularly in cell therapy and medtech marketing, he will add greatly to our capabilities in commercialisation, marketing and sales. Hans-Joachim will also work with our business development team on an executive basis to enhance our partnering and financing efforts”, says Xintela's Chairman of the Board Gregory Batcheller.

Accordingly, the proposal to the Annual General Meeting is that the Board of Directors shall be composed of four Board members, without deputies, that the Board members Gregory Batcheller, Lars Hedbys and Maarten de Chateau are re-elected and that Hans-Joachim Simons is elected new member of the Board.